The results reviewed above suggest that selective NOPR agonists may represent a promising strategy to treat addiction, particularly in alcoholism. Non-peptide, orally-available and brain-penetrant NOPR agonists have been developed and seem to have acceptable safety and tolerability. Some of these may soon become ready for clinical evaluation.
